

C 1

6. (amended) A compound as claimed in claim 1 wherein R<sup>2</sup> is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>2</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with Het<sup>2</sup> or R<sup>11</sup>.

7. (amended) A compound as claimed in claim 1 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl and -X-R<sup>2</sup> is Het<sup>1</sup>.

8. (amended) A compound as claimed in claim 1 wherein p is 1 or 2 and each R<sup>1</sup> is chloro.

9. (amended) A compound as claimed in claim 1 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl, -X-R<sup>2</sup> is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents, and p is 2 whereby both R<sup>1</sup> substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.

D 2 1 2  
11. (amended) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 1.

C 3  
Please add Claims 19-55 as follows:

19. (new) A compound as claimed in claim 2 wherein X is a direct bond, at least one of R<sup>3</sup> and R<sup>4</sup> is hydrogen, and R<sup>2</sup> is 3-pyridinyl optionally substituted in the 6 position with an optionally substituted alkyl or acyl group are excluded.

20. (new) A compound as claimed in claim 3 wherein X is a direct bond, at least one of R<sup>3</sup> and R<sup>4</sup> is hydrogen, and R<sup>2</sup> is 3-pyridinyl optionally substituted in the 6 position with an optionally substituted alkyl or acyl group are excluded.

21. (new) A compound as claimed in claim 2 wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.

C3

22. (new) A compound as claimed in claim 3 wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.

23. (new) A compound as claimed in claim 4 wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.

24. (new) A compound as claimed in claim 2 wherein R<sup>2</sup> is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>2</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with Het<sup>2</sup> or R<sup>11</sup>.

25. (new) A compound as claimed in claim 3 wherein R<sup>2</sup> is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>2</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with Het<sup>2</sup> or R<sup>11</sup>.

26. (new) A compound as claimed in claim 4 wherein R<sup>2</sup> is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>2</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with Het<sup>2</sup> or R<sup>11</sup>.

27. (new) A compound as claimed in claim 5 wherein R<sup>2</sup> is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het<sup>2</sup>, R<sup>11</sup> and C<sub>1-4</sub>alkyl optionally substituted with Het<sup>2</sup> or R<sup>11</sup>.

C 3

28. (new) A compound as claimed in claim 2 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl and -X-R<sup>2</sup> is Het.

29. (new) A compound as claimed in claim 3 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl and -X-R<sup>2</sup> is Het<sup>1</sup>.

30. (new) A compound as claimed in claim 4 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl and -X-R<sup>2</sup> is Het<sup>1</sup>.

31. (new) A compound as claimed in claim 5 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl and -X-R<sup>2</sup> is Het<sup>1</sup>.

32. (new) A compound as claimed in claim 6 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl and -X-R<sup>2</sup> is Het<sup>1</sup>.

33. (new) A compound as claimed in claim 2 wherein p is 1 or 2 and each R<sup>1</sup> is chloro.

34. (new) A compound as claimed in claim 3 wherein p is 1 or 2 and each R<sup>1</sup> is chloro.

35. (new) A compound as claimed in claim 4 wherein p is 1 or 2 and each R<sup>1</sup> is chloro.

36. (new) A compound as claimed in claim 5 wherein p is 1 or 2 and each R<sup>1</sup> is chloro.

37. (new) A compound as claimed in claim 6 wherein p is 1 or 2 and each R<sup>1</sup> is chloro.

38. (new) A compound as claimed in claim 7 wherein p is 1 or 2 and each R<sup>1</sup> is chloro.

39. (new) A compound as claimed in claim 2 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl, -X-R<sup>2</sup> is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents, and p is 2 whereby both R<sup>1</sup> substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.

40. (new) A compound as claimed in claim 3 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl, -X-R<sup>2</sup> is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents, and p is 2 whereby both R<sup>1</sup> substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.

C 3

41. (new) A compound as claimed in claim 4 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl, -X-R<sup>2</sup> is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents, and p is 2 whereby both R<sup>1</sup> substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.
42. (new) A compound as claimed in claim 5 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl, -X-R<sup>2</sup> is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents, and p is 2 whereby both R<sup>1</sup> substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.
43. (new) A compound as claimed in claim 6 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl, -X-R<sup>2</sup> is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents, and p is 2 whereby both R<sup>1</sup> substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.
44. (new) A compound as claimed in claim 7 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl, -X-R<sup>2</sup> is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents, and p is 2 whereby both R<sup>1</sup> substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.
45. (new) A compound as claimed in claim 8 wherein R<sup>3</sup> and R<sup>4</sup> are both methyl, -X-R<sup>2</sup> is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents, and p is 2 whereby both R<sup>1</sup> substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> substituents.
46. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 2.
47. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 3.
48. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 4.

C3

49. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 5.

50. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 6.

51. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 7.

52. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 8.

53. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 9.

54. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 10.

55. (new) A compound as claimed in claim 2 wherein the compound of formula (I) contains an ester function.